Rosiglitazone for Type 2 Diabetes Mellitus
Rosiglitazone, the second thiazolidinedione derivative to be marketed in the USA for treatment of type 2 diabetes, has been approved by the FDA for use either alone or combined with meformin....
Cannot Access - We are sorry, but you cannot access the requested article.
If you have already purchased this article, or have a subscription to The Medical Letter on Drugs and Therapeutics, please login or register to view it online.
If you have already purchased this article, or have a subscription to The Medical Letter on Drugs and Therapeutics, please login or register to view it online.
Information about the article:
Title: Rosiglitazone for Type 2 Diabetes Mellitus
Publication: The Medical Letter on Drugs and Therapeutics
Issue #: 1059
Article Code: 1059a
Date: August 13, 1999
Volume: 41
Pages: 71-73
Publication: The Medical Letter on Drugs and Therapeutics
Issue #: 1059
Article Code: 1059a
Date: August 13, 1999
Volume: 41
Pages: 71-73
Subscribe to The Medical Letter on Drugs and Therapeutics for instant access to this article. Add this downloadable, electronic article to your cart (U.S. English version only)